BTG Licenses Novel Anticancer Compound to Onyx Pharmaceuticals
News Nov 10, 2008
Under the terms of the agreement, BTG will receive an upfront payment of $13m and has the potential to receive development milestone payments of up to $72m plus additional payments of up to $235m relating to product approval and achievement of commercial milestones. BTG will also receive a royalty on any future sales worldwide.
“Onyx has a strong track record in developing and commercializing novel cancer therapeutics, as evidenced by their success with Nexavar®, and we see the company as an ideal partner to take BGC 945 forward,” commented Louise Makin, BTG’s chief executive officer. “This agreement is in line with our strategy to realize value from our current pipeline as we focus new investments on acquiring and developing later-stage products.”
BTG has progressed BGC 945 into late-stage preclinical development in collaboration with The Institute of Cancer Research (ICR) where the compound was discovered. BTG will share approximately 10% of the upfront and milestone revenues it receives relating to BGC 945 with ICR plus a pass-through royalty.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019